Human bikunin
First Claim
Patent Images
1. An isolated nucleic acid sequence, wherein the nucleic acid encodes a protein having serine protease inhibitory activity, comprising one of the following amino acid sequences:
(SEQ ID NO;
52) ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE150 ACMLRCFRQQ ENPPLPLGSK;
170 (SEQ ID NO;
49)
MAQLCGL RRSRAFLALL GSLLLSGVLA−
1 ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE150 ACMLRCFRQQ ENPPLPLGSK VVVLAGLFVM VLILFLGASM VYLIRVARRN200 QERALRTVWS SGDDKEQLVK NTYVL;
225 (SEQ ID NO;
71) ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE150 ACMLRCFRQQ ENPPLPLGSK VVVLAGLFVM VLILFLGASM VYLIRVARRN200 QERALRTVWS SGDDKEQLVK NTYVL;
225 (SEQ ID NO;
2) AGSFLAWL GSLLLSGVLA−
1 ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE150 ACMLRCFRQQ ENPPLPLGSK VVVLAGAVS179 (SEQ ID NO;
45)
MLR AEADGVSRLL GSLLLSGVLA−
1 ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE150 ACMLRCFRQQ ENPPLPLGSK VVVLAGLFVM VLILFLGASM VYLIRVARRN200 QERALRTVWS SGDDKEQLVK NTYVL;
225 (SEQ ID NO;
47)
MAQLCGL RRSRAFLALL GSLLLSGVLA−
1 ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE150 ACMLRCFRQQ ENPPLPLGSK VVVLAGLFVM VLILFLGASM VYLIRVARRN200 QERALRTVWS FGD;
213 (SEQ ID NO;
70) ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE150 ACMLRCFRQQ ENPPLPLGSK VVVLAGLFVM VLILFLGASM VYLIRVARRN200 QERALRTVWS FGD;
213 (SEQ ID NO;
4)
IHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN50 YLTKEECLKK CATV;
64 (SEQ ID NO;
6) YEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE150 ACMLRCFRQ;
159 (SEQ ID NO;
3)
IHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE150 ACMLRCFRQ;
159 (SEQ ID NO;
50)
CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF100 NYEEYCTANA VTGPGRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE150 ACMLRC; and
156 (SEQ ID NO;
1) ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE150 ACMLRCFRQQ ENPPLPLGSK VVVLAGAVS.179
0 Assignments
0 Petitions
Accused Products
Abstract
The instant invention provides for proteins, polypeptides, nucleic acid sequences, constructs, expression vectors, host cells, pharmaceutical compositions of, and methods for using human placental bikunin, serine protease inhibitor domains, and fragments thereof
-
Citations
6 Claims
-
1. An isolated nucleic acid sequence, wherein the nucleic acid encodes a protein having serine protease inhibitory activity, comprising one of the following amino acid sequences:
(SEQ ID NO;
52)ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRCFRQQ ENPPLPLGSK; 170 (SEQ ID NO;
49)
MAQLCGLRRSRAFLALL GSLLLSGVLA −
1ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRCFRQQ ENPPLPLGSK VVVLAGLFVM VLILFLGASM VYLIRVARRN 200 QERALRTVWS SGDDKEQLVK NTYVL; 225 (SEQ ID NO;
71)ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRCFRQQ ENPPLPLGSK VVVLAGLFVM VLILFLGASM VYLIRVARRN 200 QERALRTVWS SGDDKEQLVK NTYVL; 225 (SEQ ID NO;
2)AGSFLAWL GSLLLSGVLA −
1ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRCFRQQ ENPPLPLGSK VVVLAGAVS 179 (SEQ ID NO;
45)
MLRAEADGVSRLL GSLLLSGVLA −
1ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRCFRQQ ENPPLPLGSK VVVLAGLFVM VLILFLGASM VYLIRVARRN 200 QERALRTVWS SGDDKEQLVK NTYVL; 225 (SEQ ID NO;
47)
MAQLCGLRRSRAFLALL GSLLLSGVLA −
1ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRCFRQQ ENPPLPLGSK VVVLAGLFVM VLILFLGASM VYLIRVARRN 200 QERALRTVWS FGD; 213 (SEQ ID NO;
70)ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRCFRQQ ENPPLPLGSK VVVLAGLFVM VLILFLGASM VYLIRVARRN 200 QERALRTVWS FGD; 213 (SEQ ID NO;
4)
IHDF CLVSKVVGRC RASMPRWWYNVTDGSCQLFV YGGCDGNSNN 50 YLTKEECLKK CATV; 64 (SEQ ID NO;
6)YEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRCFRQ; 159 (SEQ ID NO;
3)
IHDF CLVSKVVGRC RASMPRWWYNVTDGSCQLFV YGGCDGNSNN 50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRCFRQ; 159 (SEQ ID NO;
50)
CLVSKVVGRC RASMPRWWYNVTDGSCQLFV YGGCDGNSNN 50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPGRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRC; and 156 (SEQ ID NO;
1)ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRCFRQQ ENPPLPLGSK VVVLAGAVS. 179 - View Dependent Claims (2, 3, 4, 5, 6)
Specification